Cancer Research and Biotechnology AG (CRB) is a Swiss preclinical biopharma company developing a novel small molecule treatment for cancer, based in its discovery and innovation on reversing carcinogenesis. Preclinical studies: pancreatic cancer, triple-negative breast cancer, and colon cancer.

Products, services, technology

CRB091, oncology, preclinical. The CRB team has identified a root cause or amplifier of many human cancers. This constitutes the first step towards an effective curative and protective method to treat present and potential patients. Pancreatic cancer, triple-negative breast cancer, and colon cancer.

Cooperation possibilities

Funding: Value derives from knowledge of why and how cancer is started in the body, and developing drugs for a fast-to-market pathway.
Research: Therapeutic agents

Some insights
Facts & figures
  • Type of organization
    Private company
  • Year of foundation
  • Number of employees in Switzerland